#49905
Re: Chicharros USA - bolsa internacional
IMGN
Subiendo un 9,46%... (4,28$)
Primer nivel a batir, los 4,35, y luego, los 4,53....
En principio, el miércoles tienen que entregarse los abstracts...
ASCO meeting: Abstracts will be released from the American Society of Clinical Oncology Annual Meeting on May 13. The data dump will include key releases from Bristol-Myers Squibb (NYSE:BMY), bluebird bio (NASDAQ:BLUE), Roche (OTCQX:RHHBY), Amgen (NASDAQ:AMGN), Allogene Therapeutics (NASDAQ:ALLO), Genmab (NASDAQ:GMAB), Merck (NYSE:MRK), Karyopharm Therapeutics (NASDAQ:KPTI), AstraZeneca (NYSE:AZN), MacroGenics (NASDAQ:MGNX), Exelixis (NASDAQ:EXEL), Myovant Sciences (NYSE:MYOV), Johnson & Johnson, Seattle Genetics (NASDAQ:SGEN), GlaxoSmithKline (NYSE:GSK), BeiGene (NASDAQ:BGNE), Arvinas (NASDAQ:ARVN), Gilead Sciences (NASDAQ:GILD), Takeda Pharmaceuticals (NYSE:TAK), Iovance Biotherapeutics (NASDAQ:IOVA), AVEO Pharmaceuticals (NASDAQ:AVEO), Blueprint Medicines (NASDAQ:BPMC), Progenics Pharmaceuticals (NASDAQ:PGNX), Kura Oncology (NASDAQ:KURA), Autolus Therapeutics (NASDAQ:AUTL), ImmunoGen (NASDAQ:IMGN), CytomX Therapeutics (NASDAQ:CTMX) and Celyad (NASDAQ:CYAD).
Un saludo
Subiendo un 9,46%... (4,28$)
Primer nivel a batir, los 4,35, y luego, los 4,53....
En principio, el miércoles tienen que entregarse los abstracts...
ASCO meeting: Abstracts will be released from the American Society of Clinical Oncology Annual Meeting on May 13. The data dump will include key releases from Bristol-Myers Squibb (NYSE:BMY), bluebird bio (NASDAQ:BLUE), Roche (OTCQX:RHHBY), Amgen (NASDAQ:AMGN), Allogene Therapeutics (NASDAQ:ALLO), Genmab (NASDAQ:GMAB), Merck (NYSE:MRK), Karyopharm Therapeutics (NASDAQ:KPTI), AstraZeneca (NYSE:AZN), MacroGenics (NASDAQ:MGNX), Exelixis (NASDAQ:EXEL), Myovant Sciences (NYSE:MYOV), Johnson & Johnson, Seattle Genetics (NASDAQ:SGEN), GlaxoSmithKline (NYSE:GSK), BeiGene (NASDAQ:BGNE), Arvinas (NASDAQ:ARVN), Gilead Sciences (NASDAQ:GILD), Takeda Pharmaceuticals (NYSE:TAK), Iovance Biotherapeutics (NASDAQ:IOVA), AVEO Pharmaceuticals (NASDAQ:AVEO), Blueprint Medicines (NASDAQ:BPMC), Progenics Pharmaceuticals (NASDAQ:PGNX), Kura Oncology (NASDAQ:KURA), Autolus Therapeutics (NASDAQ:AUTL), ImmunoGen (NASDAQ:IMGN), CytomX Therapeutics (NASDAQ:CTMX) and Celyad (NASDAQ:CYAD).
Un saludo